1 transaction in KRYS reported by 1 member of Congress under the STOCK Act, most recent trade Dec 12, 2022. Reported transactions, not recommendations.
About Krystal Biotech, Inc. (KRYS): stock profile, AI score and financials
Krystal Biotech, Inc. (KRYS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRYS at 78.6/100 on a composite quality score built from its SEC filings, placing it at rank #48 of 2,925 stocks — the top 5% of the AI-ranked universe. KRYS scores in the top quartile across profitability (98.1), free cash flow (96.8), revenue growth (95.5). Areas of concern include revenue scale (34.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Krystal Biotech, Inc. reports quarterly revenue of $119.2M, net income of $54.8M, an operating margin of 49.0%. Top institutional holders of KRYS by reported 13-F value include FMR, BlackRock, Avoro Capital Advisors, based on the most recent SEC filings. KRYS trades on the Nasdaq exchange and files with the SEC under CIK 1711279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Krystal Biotech, Inc. directly from SEC EDGAR.